



Veloxis Pharmaceuticals A/S

2015 Annual report

Investor Conference

Craig A. Collard, President and CEO
Johnny Stilou, CFO
Alastair McEwan, COO

09-March-2016, 3pm CET

Dial-in Numbers:
Denmark +45 38 32 28 69
UK +44(0) 20 3427 0503
USA +1 646 254 3361
Access code 6300894

Forward-Looking Statements

This presentation contains forward-looking statements. All statements other than statements of historical facts included in this presentation are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control.

Words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “will” and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding potential future regulatory approvals for ENVARSUS XR® (formerly LCP-Tacro™), and commercial forecasts are considered forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate.

Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to our ability to obtain regulatory approval for, and commercialize, ENVARSUS XR®; our ability to hire and retain personnel in a competitive industry; our reliance on third parties to manufacture and distribute ENVARSUS XR®; competition from existing therapies and therapies that are currently under development, including Prograf® (tacrolimus), Advagraf® /Astagraf XL® (tacrolimus), generic tacrolimus products, and Nulojix® (belatacept); whether we are able to obtain additional financing, if needed; risks of maintaining protection for our intellectual property; risks of an adverse determination in intellectual property litigation; and risks associated with stringent government regulation of the biopharmaceutical industry.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date hereof. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. We do not have a policy of updating or revising forward-looking statements and, except as required by law, assume no obligation to update any forward-looking statements.



Agenda

- Veloxis 2015 Highlights
- Commercial Outlook
- Financials 2015
- Summary

2015 Highlights

- Commercial launch in the U.S.
 - Envarsus XR is indicated for the prophylaxis of organ rejection in kidney transplant patients converted from tacrolimus immediate-release formulations
- Envarsus XR granted U.S. orphan drug exclusivity for the approved indication
- U.S. commercial infrastructure in place
 - Majority of Field Force hired, on-board, trained and active in the field
- EU commercialization activities progressing successfully
 - Envarsus EU launch roll-outs continue in line with plans via Chiesi
 - Belgium Launch planned for September 2016
- Unique J-Code reimbursement status received in the U.S.
- Envarsus XR demonstrated improved pharmacokinetic profile in African-American transplant patients

Veloxis Commercial Outlook



Commercial Outlook

- Company has added four new executive level members to expand commercial capabilities
- Closure of Denmark office
 - Will be completed by August 2016
- New Financing announced
 - Term loan gives monies needed for commercial growth in the U.S. market
- ROW Partnering
- U.S. Product launch moving forward as planned
 - 54 Top tier transplant centers make up 40% of US patient opportunity
 - 30% of top centers have used Envarsus since launch
- New training of sales force planned for March 2016



Financial Results



Financial result 2015

- Result and cash position in line with previously announced full year outlook

MDKK	Outlook 2015	Full year		Outlook 2016
		2015	2014	
Net revenue		14,2	123,4	
Production costs		(15,2)	(3,2)	
Gross profit		(1,0)	120,2	
Sales and marketing		(66,2)	(41,3)	
Research and development		(76,3)	(90,1)	
General and administration		(53,6)	(47,4)	
Operating result	(175) - (205)	(197,1)	(58,6)	(120) - (160)
Net result	(155) - (185)	(176,1)	(36,3)	(120) - (160)
Cash position year-end	100 - 130	107,7	270,4	

Summary



Q & A

Thank you for your attention!

